• BerGenBio is focused on therapeutics that target the epithelial-mesenchymal-transition (EMT) in cancer, considered to play a critical role in tumor metastasis.

  • Rigel and BerGenBio are in an agreement for Rigel's preclinical candidate, R428 (now referred to as BGB324), an Axl kinase inhibitor for oncology.

  • BerGenBio has initiated a Phase 1 clinical studies for BGB324 in acute myeloid leukemia (AML) and a Phase 1b in non-small cell lung cancer (NSCLC).